Skip to main content

Table 6 Summary of overall findings including HER2/neu reactions in the 125 cases

From: Systematic assessment of HER2/neu in gynecologic neoplasms, an institutional experience

Overall information HER2/neu
Groups Neoplasm Median age n % POS (n) POS (%)
Group I CCCA 54 11 8.8 % 3 27.3 %
Group II SCA 58 45 36.0 % 5 11.1 %
Group III ENAdCA 61.5 28 22.4 % 0 0.0 %
Group IV MxSEAdCA 65 26 20.8 % 1 3.8 %
Group V Other 54 15 12.0 % 1 6.7 %
  1. CCCA clear cell carcinoma, SCA serous carcinoma, ENAdCA endometrioid adenocarcinoma, MxSEAdCA mixed surface epithelial adenocarcinomas, Other other neoplasms, POS positive